GOETZL EDWARD J has a total of 15 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2002. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and EPO (European Patent Office). Its main competitors in its focus markets measurement, pharmaceuticals and biotechnology are NANOSOMIX INC, PROCOGNIA ISRAEL LTD and EXPRESSION PATHOLOGY INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | United States | 5 | |
#3 | EPO (European Patent Office) | 4 |
# | Industry | |
---|---|---|
#1 | Measurement | |
#2 | Pharmaceuticals | |
#3 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Analysing materials | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Microorganisms | |
#5 | Peptides | |
#6 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Goetzl Edward J | 11 |
#2 | Goetzl Edward | 4 |
#3 | An Songzhu | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020123884A1 | Neuron-derived exosomes and their biomarkers for the diagnosis, prognosis, and treatment of traumatic brain injury and alzheimer's disease | |
US2020341011A1 | Astrocyte exosome complement-based assay for neuroinflammation in alzheimer's disease and uses thereof | |
US2019011460A1 | Specialized excitatory synaptic protein biomarkers of plasma neuronal exosomes for prediction and staging of Alzheimer's disease | |
WO2018144070A1 | Endothelial cell derived exosomes and uses thereof | |
US2017343563A1 | Drug efficacy test method for dementias utilizing astrocyte-derived exosomes | |
EP3374026A1 | Platelet biomarkers and diagnostic methods for vascular diseases |